Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity

Johannes Sam; Sara Colombetti; Tanja Fauti; Andreas Roller; Marlene Biehl; Linda Fahrni; Valeria Nicolini; Mario Perro; Tapan Nayak; Esther Bommer; Anne Schoenle; Maria Karagianni; Marine Le Clech; Nathalie Steinhoff; Christian Klein; Pablo Umaña; Marina Bacac

doi:10.3389/fonc.2021.650149

Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity

Front Oncol. 2021 Feb 3:11:650149. doi: 10.3389/fonc.2021.650149. eCollection 2021.

Authors

Johannes Sam¹, Sara Colombetti¹, Tanja Fauti¹, Andreas Roller², Marlene Biehl¹, Linda Fahrni¹, Valeria Nicolini¹, Mario Perro¹, Tapan Nayak², Esther Bommer¹, Anne Schoenle¹, Maria Karagianni¹, Marine Le Clech¹, Nathalie Steinhoff¹, Christian Klein¹, Pablo Umaña¹, Marina Bacac¹

Affiliations

¹ Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.
² Roche Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.

Abstract

[This corrects the article .].

Keywords: T-cell bispecific antibody; carcinoembryonic antigen T-cell bispecific antibody; combination; humanized mice; immunotherapy; programmed death–ligand 1; solid tumors.

Publication types

Published Erratum